Cyclacel Pharmaceuticals Inc. Overview

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company operating within the health care sector, is primarily focused on biotechnology. The company is based in Berkeley Heights, United States, and extends its services to customers in both the United States and the United Kingdom. Cyclacel’s mission is to discover and develop small molecule cycle inhibitors aimed at the effective treatment of cancer and other serious diseases. This mission is pursued through rigorous research and development efforts. The company’s stock is publicly traded on the Nasdaq stock exchange, and more information can be found on their official website at www.cyclacel.com .

Financial Snapshot

As of July 17, 2025, Cyclacel Pharmaceuticals Inc. had a close price of $13.07. The company’s market capitalization stands at $13,040,000 USD. Over the past year, the stock has experienced significant volatility, with a 52-week high of $597.6 recorded on October 21, 2024, and a 52-week low of $3.08 on July 6, 2025. The price-to-earnings ratio is currently at -0.028009, reflecting the company’s financial performance and market valuation.

Industry and Sector

Cyclacel Pharmaceuticals operates within the biotechnology industry, a segment of the broader health care sector. The company’s focus on developing small molecule cycle inhibitors positions it as a key player in the biopharmaceutical landscape, particularly in the realm of cancer treatment and other serious diseases.

Conclusion

Cyclacel Pharmaceuticals Inc. continues to navigate the challenges and opportunities within the biotechnology sector. With its commitment to innovation and development of novel treatments, the company remains a significant entity in the health care industry. Investors and stakeholders are closely monitoring its progress, especially given the recent fluctuations in its stock price and market capitalization.